Can I Take Glycine with TB-500?

What Are TB-500 and Glycine, and Why Do People Combine Them?

TB-500 is a synthetic 17-amino-acid peptide corresponding to the actin-binding domain of thymosin beta-4, a 43-amino-acid protein expressed in virtually all nucleated human cells. Researchers identified thymosin beta-4 as a primary regulator of actin polymerization, wound closure, and angiogenesis across multiple tissue types. The active fragment retains the Ac-LKKTETQ sequence responsible for most of the parent molecule's repair signaling.

Glycine is the smallest amino acid. The body produces roughly 3 g per day endogenously, yet dietary intake from a modern protein-restricted diet is often insufficient for collagen turnover, sleep quality, and glutathione recycling. A 2012 systematic review in Amino Acids found that conditionally essential status for glycine is supported by nitrogen-balance data across several metabolic states. [1]

People combine the two because both are promoted in the research-peptide community for connective-tissue recovery. The logic is straightforward: TB-500 may accelerate tissue remodeling at the cell-signaling level, while glycine supplies the raw substrate that collagen synthesis requires.

TB-500's Mechanism in Brief

TB-500 binds G-actin, reducing treadmilling and freeing monomers for cytoskeletal restructuring in migrating keratinocytes and endothelial cells. A 2010 study in the Journal of Investigative Dermatology demonstrated that thymosin beta-4 accelerated full-thickness dermal wound closure in a murine model by upregulating matrix metalloproteinases and laminin-5. [2] Separately, thymosin beta-4 suppresses NF-kB-driven inflammatory signaling, a finding confirmed in a 2007 Annals of the New York Academy of Sciences review of its cardioprotective properties. [3]

Glycine's Mechanism in Brief

Glycine makes up roughly 33% of collagen by mass. Every third residue in the triple-helix is glycine, and rate-limiting availability of glycine can slow collagen deposition. Beyond structural roles, glycine acts as an inhibitory neurotransmitter in the brainstem and spinal cord via strychnine-sensitive glycine receptors, which is why a 3 g oral dose reliably shortens sleep-onset latency. A 2012 double-blind crossover trial (N=11) published in Sleep and Biological Rhythms confirmed reduced fatigue and improved polysomnographic sleep quality with glycine supplementation. [4]

Is the TB-500 and Glycine Interaction Pharmacokinetic or Pharmacodynamic?

The interaction is pharmacodynamic, not pharmacokinetic. Pharmacokinetic interactions occur when one agent alters the absorption, distribution, metabolism, or excretion of another. TB-500 is a small peptide administered subcutaneously; it bypasses hepatic first-pass metabolism entirely and is degraded by tissue peptidases. Oral glycine is absorbed in the proximal small intestine via sodium-coupled neutral amino-acid transporters and cleared renally. The two compounds never share a metabolic enzyme pathway.

What "Pharmacodynamic Additive" Means Clinically

Additive pharmacodynamic effects happen when two agents act on the same biological endpoint through different molecular routes. Both glycine and TB-500 support extracellular-matrix deposition, though by distinct mechanisms:

• TB-500 upregulates MMP expression and endothelial migration signals.
• Glycine supplies the structural amino-acid substrate and stimulates fibroblast collagen gene expression directly, as shown in a 2018 Nutrients review of amino acids in connective-tissue repair. [5]

The combined effect on net collagen output may exceed either agent alone, but no controlled human trial has tested this co-administration directly. That gap matters. No published RCT supports a synergistic or even reliably additive outcome in humans.

Anti-Inflammatory Overlap

Both agents independently reduce markers of acute inflammation. Glycine suppresses lipopolysaccharide-induced macrophage activation through glycine-gated chloride channels, a mechanism reviewed in a 2003 Current Opinion in Clinical Nutrition and Metabolic Care article. [6] TB-500 downregulates NF-kB in cardiac and vascular tissue. [3] Whether combined use results in excessive immunosuppression at clinical doses is unknown. At standard research doses, neither agent produces clinically significant immunosuppression, but monitoring for signs of atypical infection is reasonable during longer protocols.

Does Glycine Affect Blood Sugar When Combined with TB-500?

Glycine has a modest glucoregulatory effect that deserves attention, particularly for users who are also metabolically vulnerable or on GLP-1 receptor agonists.

Glycine's GLP-1 Connection

A 2015 randomized crossover study (N=12) in Diabetes Care showed that oral glycine 5 g co-ingested with glucose increased plasma GLP-1 by approximately 50% compared with glucose alone, and reduced the postprandial glucose area under the curve by roughly 10%. [7] This is a modest effect, but it may stack with other agents that lower glucose or delay gastric emptying.

TB-500 itself has no direct glycemic mechanism identified in current literature. Still, compounded peptide protocols sometimes include other agents (BPC-157, insulin-sensitizing compounds) alongside TB-500. Users on multidrug peptide stacks should track fasting glucose at 4-week intervals simply as a baseline-protection measure.

Practical Glycemic Monitoring

Users with normal metabolic function taking glycine at 3 g before bed are unlikely to experience hypoglycemia. The risk increases if glycine is taken alongside sulfonylureas, insulin, or GLP-1 receptor agonists. A fasting glucose measurement before starting the combined protocol, and again at weeks 4 and 8, is an inexpensive safeguard. The American Diabetes Association's 2024 Standards of Care define impaired fasting glucose as 100 to 125 mg/dL, a threshold worth knowing before layering glycemic-active supplements. [8]

Sleep Quality: Does Glycine Interfere with or Support TB-500 Recovery?

Sleep is where the TB-500 and glycine combination may offer its clearest benefit, because tissue repair is heavily concentrated in slow-wave sleep.

Growth Hormone Secretion During Sleep

The majority of daily growth hormone (GH) secretion occurs during the first slow-wave sleep episode, roughly 60 to 90 minutes after sleep onset. GH drives IGF-1 production, which in turn supports protein synthesis in tendons, cartilage, and muscle. Anything that deepens or lengthens slow-wave sleep could, in theory, amplify the anabolic context in which TB-500 operates.

A 2007 study in Sleep confirmed that glycine administration before bed increased slow-wave sleep duration and reduced core body temperature, the latter being a known physiological correlate of deeper sleep stages. [9] If TB-500 was injected earlier that day or the day before, glycine-enhanced slow-wave sleep may improve the hormonal milieu during which tissue remodeling occurs. This mechanism is biologically plausible but remains speculative in the absence of a combined trial.

No Sedation Risk from Glycine

Glycine at 3 g does not produce pathological sedation, respiratory depression, or next-day cognitive impairment in published data. The 2012 crossover study by Bannai et al. Found no adverse effects on daytime alertness at this dose. [4] TB-500 has no known CNS-sedating mechanism. Taking both together carries no additive sedation risk.

Dosing Windows and Practical Scheduling

No mandatory time-separation between glycine and TB-500 exists based on current pharmacokinetic data. A practical daily schedule can still be organized around each compound's purpose.

Sample Protocol Schedule

• Morning (injection day): TB-500 2.5 mg subcutaneous, typically into abdominal fat or near the target tissue region per the prescribing clinician's instructions.
• Evening (every night): Glycine 3 g in water, 30 to 60 minutes before bed.
• Injection frequency: TB-500 is typically dosed twice weekly during a 4 to 6 week loading phase, based on compounding-clinic protocols reviewed by the HealthRX medical team.

TB-500 reaches peak plasma concentration within 30 minutes of subcutaneous injection in rodent models, per pharmacokinetic data cited in a 2010 Regulatory Peptides study. [10] By evening, circulating peptide levels are well into the terminal elimination phase, so there is no meaningful pharmacokinetic overlap with orally absorbed glycine.

Dose-Response Considerations for Glycine

The 3 g pre-sleep dose is the best-studied amount for sleep quality. Higher doses (up to 9 g) have been tested for metabolic outcomes without significant adverse effects in short-term studies. For connective-tissue support specifically, a 2019 study in Nutrients found that 15 g of gelatin (equivalent to roughly 4.5 g glycine) taken 60 minutes before exercise increased serum collagen synthesis markers. [11] Users stacking with TB-500 for tendon or ligament repair might consider a second 3 to 5 g glycine dose 45 to 60 minutes before a training session, though this remains off-label and should be discussed with a clinician.

What the Evidence Does Not Yet Tell Us

Direct human trial data on TB-500 co-administered with glycine does not exist. This is a meaningful absence. The evidence base for TB-500 itself in humans is thin: most mechanistic studies used thymosin beta-4 in rodent wound and cardiac models, and the few human data points come from phase I/II trials in dry-eye disease and epidermolysis bullosa rather than musculoskeletal repair.

The FDA has not approved thymosin beta-4 or TB-500 for any indication. It is available in the United States through 503A compounding pharmacies that prepare individualized prescriptions. The FDA's compounding regulations under 21 CFR Part 207 apply to these preparations. [12] Patients should source TB-500 only through a licensed compounding pharmacy with a valid prescription from a licensed clinician.

Glycine is classified as Generally Recognized as Safe (GRAS) by the FDA. Its safety profile in healthy adults is well-established up to 9 g per day in published trials, with gastrointestinal softening being the most commonly reported adverse effect at higher doses.

Safety, Contraindications, and Monitoring

Who Should Be Cautious

• Metabolic syndrome or pre-diabetes: Monitor fasting glucose given glycine's GLP-1-stimulating effect. [7]
• Active autoimmune disease: Both agents modulate immune signaling; use only under physician supervision.
• Pregnancy or lactation: No safety data exist for TB-500 in pregnancy. Glycine at dietary levels is considered safe; pharmacological supplementation during pregnancy has not been adequately studied.
• Concurrent GLP-1 receptor agonist therapy: Glycine may add a modest glucose-lowering effect. Inform your prescriber.

Monitoring Protocol at HealthRX

The HealthRX medical team recommends the following laboratory and symptom checks for patients using TB-500 alongside glycine:

1. Fasting glucose and HbA1c at baseline and at 8 weeks.
2. CRP or ESR at baseline to document inflammatory status before starting either agent.
3. Subjective sleep-quality log (Pittsburgh Sleep Quality Index) at weeks 0, 4, and 8.
4. Injection-site inspection at every dose for erythema, induration, or nodule formation.

No hepatotoxicity signals have been attributed to either compound in published literature. Liver function testing is not routinely required but may be ordered by the treating physician at their discretion.

Regulatory and Quality-Control Notes

TB-500 sold outside a licensed compounding pharmacy, including most "research chemical" or "for laboratory use only" vendors, is not subject to pharmaceutical-grade quality controls. A 2023 independent mass-spectrometry analysis of gray-market peptide products found that a meaningful fraction of products were dosed inaccurately or contained residual synthesis byproducts (acetate, trifluoroacetate counter-ions). Patients should request a Certificate of Analysis from their compounding pharmacy confirming identity, purity, and endotoxin levels before injecting any compounded peptide.

Glycine supplements are broadly available and generally well-manufactured, though label accuracy varies. The NIH Office of Dietary Supplements maintains a database of supplement regulatory considerations useful for clinicians advising patients. [13]

Clinical Bottom Line

Glycine and TB-500 do not interact pharmacokinetically. Their pharmacodynamic overlap in collagen synthesis and inflammation reduction may be additive, which is the basis for their combined use in tissue-repair protocols. The best-supported practical regimen is 3 g glycine orally 30 to 60 minutes before sleep every night, paired with TB-500 2.5 mg subcutaneous twice weekly on a clinician-supervised protocol.

Patients with impaired fasting glucose (100 to 125 mg/dL per ADA 2024 criteria [8]) should track fasting glucose at 4-week intervals when adding glycine, given its documented ability to increase GLP-1 secretion by approximately 50% in a postprandial context. [7]